Sartorius | SRT3 - Cash And Equivalent


Sartorius reported EUR230.7M in Cash and Equivalent for its fiscal quarter ending in September of 2026.





Cash And Equivalent Change Date
Akebia Therapeutics USD 159.25M 3.71M Sep/2026
Alaunos Therapeutics USD 124K 230K Jun/2026
Avita Medical AUD 9.14M 1.1M Jun/2026
Dianthus Therapeutics USD 55.69M 54.86M Sep/2026
Ionis Pharmaceuticals USD 296.3M 53.76M Sep/2026
IQVIA Holdings USD 2.25B 340M Sep/2026
Moderna USD 1.2B 528M Sep/2026
Organon & Co USD 1.46B 323M Sep/2026
Revvity USD 592.8M 430.14M Sep/2026
Sartorius EUR 230.7M 60.3M Sep/2026
Tectonic Therapeutic USD 227.07M 9.83M Jun/2026
Viatris USD 1.79B 902.7M Sep/2026
Xeris Pharmaceuticals USD 131.08M 9.33M Sep/2026